16 citations
,
May 2019 in “International Journal of Women's Dermatology” This study reviewed and categorized dermatological drugs for pregnancy and lactation according to new FDA labeling guidelines, which replaced simplistic letter categories with detailed information, aiming to improve prescribing decisions by addressing both maternal and paternal reproductive potential.
2 citations
,
August 2016 in “British Journal of Clinical Pharmacology” This study found that from 2011 to 2015, a substantial portion of women in the Netherlands dispensed finasteride or dutasteride were not using adequate contraception, prompting calls for improved risk management.
28 citations
,
September 2008 in “Current Pharmaceutical Design” This review discusses hypersensitivity reactions to anticoagulants like ASA and heparins, highlighting their rare but potentially life-threatening nature, and emphasizes the need for meticulous allergy testing to find safe alternatives.
19 citations
,
March 2018 in “Expert Opinion on Drug Safety” In this narrative review, the researchers reported that the overall safety profile of drugs used for treating spondyloarthritis is generally good, with serious adverse events being rare, but emphasized the need for rheumatologists to tailor treatments and closely monitor patients for potential adverse events.
29 citations
,
January 2016 in “CNS drugs” This review of teriflunomide for relapsing-remitting multiple sclerosis examines its clinical and safety outcomes, finding it significantly reduces relapse rates and disability progression while being generally well-tolerated.